AN2 Therapeutics Gets FDA Clearance for Phase 2 Epetraborole Trial in Polycythemia Vera

PUBT · 2d ago
AN2 Therapeutics Gets FDA Clearance for Phase 2 Epetraborole Trial in Polycythemia Vera
  • AN2 Therapeutics received FDA clearance to proceed with a Phase 2 trial of oral epetraborole for polycythemia vera.
  • The global trial is expected to begin in the fourth quarter of 2026, with regulatory clearance secured in all planned jurisdictions.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AN2 Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611020700BIZWIRE_USPR_____20261102_BW081693) on November 02, 2026, and is solely responsible for the information contained therein.